ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

NCT00490139 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

8381

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Breast

Interventions

DRUG: Lapatinib
BIOLOGICAL: Trastuzumab

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]